12.05.11
Pfizer Inc. last week completed two acquisitions that are designed to expand its skin care expertise and market reach.
On Dec. 2, the firm finished its deal for Excaliard Pharmaceuticals, Inc., a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis (skin scarring), and the day prior it closed the deal on its acquisition of Ferrosan Consumer Health’s business.
On Dec. 2, the firm finished its deal for Excaliard Pharmaceuticals, Inc., a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis (skin scarring), and the day prior it closed the deal on its acquisition of Ferrosan Consumer Health’s business.
“It is imperative at Pfizer that we continue to develop new and innovative treatments to address unmet medical needs, and there is currently no FDA-approved treatment for excessive skin scarring,” said Jose-Carlos Gutierrez-Ramos, senior vice president, biotherapeutics, worldwide R&D, Pfizer.
“Acquiring Excaliard allows us to continue the development of its lead compound EXC 001 to potentially fill a gap and bring a novel new treatment to patients.”
According to Nicholas Dean, founder and chief scientific officer of Excaliard, Pfizer will continue to develop EXC 001, “which has shown evidence of reducing scar severity in Phase 2 clinical trials.”
Additionally, Pfizer Inc. has completed its previously announced acquisition of Ferrosan Consumer Health’s business, which includes dietary supplements and a skin care brand, from Altor 2003 Fund GP Limited.
“Ferrosan Consumer Health’s innovative products and geographic footprint are a strong fit for our business,” said Paul Sturman, president, Pfizer Consumer Healthcare. “Today, we have taken an important step by adding leading brands to our existing portfolio as well as enhancing our presence in established and emerging markets such as the Nordic countries, Russia and Ukraine. Through this acquisition, we’ll have the opportunity to provide a broader portfolio of highly trusted and differentiated products to consumers.”
Headquartered in Copenhagen, Ferrosan Consumer Health today employs approximately 640 people and is engaged in the sale of science-based consumer health care products primarily in the Nordic region and the emerging markets of Russia and Central and Eastern Europe. Ferrosan Consumer Health offers a product portfolio of brands in the vitamin and probiotics categories as well as Imedeen oral skin care products.